These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22285805)

  • 41. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.
    Castells L; Esteban JI; Bilbao I; Vargas V; Allende H; Ribera E; Piron M; Sauleda S; Len O; Pahissa A; Esteban R; Guardia J; Margarit C
    Antivir Ther; 2006; 11(8):1061-70. PubMed ID: 17302376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.
    Veldt BJ; Poterucha JJ; Watt KD; Wiesner RH; Hay JE; Kremers WK; Rosen CB; Heimbach JK; Charlton MR
    Am J Transplant; 2008 Nov; 8(11):2426-33. PubMed ID: 18727694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
    Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
    Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study.
    ReViS-TC Study Group
    Transplantation; 2011 Aug; 92(3):334-40. PubMed ID: 21659948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
    Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
    Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
    Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
    Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G;
    Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thymoglobulin for steroid-resistant immune-mediated graft dysfunction during simeprevir-based antiviral treatment for post-transplantation hepatitis C: case report.
    Takeishi K; Ikegami T; Yoshizumi T; Itoh S; Harimoto N; Harada N; Tsujita E; Kimura Y; Yamashita Y; Saeki K; Oki E; Shirabe K; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):794-5. PubMed ID: 25891734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
    Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
    Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.
    Saab S; Oh MK; Ibrahim AB; Durazo F; Han S; Yersiz H; Farmer DG; Ghobrial RM; Goldstein LI; Tong MJ; Busuttil RW
    Liver Transpl; 2007 Jul; 13(7):1032-8. PubMed ID: 17600345
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
    Dumortier J; Scoazec JY; Chevallier P; Boillot O
    J Hepatol; 2004 Apr; 40(4):669-74. PubMed ID: 15030984
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.
    Hermos JA; Quach L; Gagnon DR; Weber HC; Altincatal A; Cho K; Lawler EV; Grotzinger KM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):480-8. PubMed ID: 24677630
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.
    Sanai FM; Mousa D; Al-Mdani A; Al-Shoail G; Al-Ashgar H; Al Meshari K; Al-Qahtani A; Saadeh M; Bzeizi KI; Aleid H
    J Hepatol; 2013 Jun; 58(6):1096-103. PubMed ID: 23428875
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.
    Carrión JA; Martínez-Bauer E; Crespo G; Ramírez S; Pérez-del-Pulgar S; García-Valdecasas JC; Navasa M; Forns X
    J Hepatol; 2009 Apr; 50(4):719-28. PubMed ID: 19217183
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S; Lyden E
    Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
    Kawaoka T; Hiraga N; Takahashi S; Takaki S; Tsuge M; Nagaoki Y; Hashimoto Y; Katamura Y; Miki D; Hiramatsu A; Waki K; Imamura M; Kawakami Y; Aikata H; Ochi H; Tashiro H; Ohdan H; Chayama K
    Intervirology; 2012; 55(4):306-10. PubMed ID: 21865660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.